CG Oncology (CGON) Interest Expenses (2023 - 2026)
CG Oncology's (CGON) quarterly Interest Expenses came in at $382.9 million in Q1 2026, up 338.54% YoY from $87.3 million in Q1 2025, and up 136847.14% on a QoQ basis from -$280000.0 in Q4 2025.
CG Oncology (CGON) Interest Expenses (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Interest Expenses data on file, last reported at $382.9 million in Q1 2026.
- Quarterly Interest Expenses rose 338.54% year-over-year to $382.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $382.9 million (up 338.54% YoY) and the FY2025 annual result came in at $198.5 million, up 83.57% from the prior year.
- Interest Expenses improved to $382.9 million in Q1 2026, from -$280000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $382.9 million in Q1 2026 to a low of -$280000.0 in Q4 2025.
- A 4-year average of $109.1 million and a median of $97.0 million in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses jumped 339975.56% — and 2025, when it tumbled 566.67%.
- Tracing CGON's Interest Expenses over 4 years: stood at $59000.0 in 2023, then advanced by 1.69% to $60000.0 in 2024, then plunged by 566.67% to -$280000.0 in 2025, then surged by 136847.14% to $382.9 million in 2026.
- The last three Interest Expenses figures came in at $382.9 million (Q1 2026), -$280000.0 (Q4 2025), and $190.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 386.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 386.63 Mn |
| Jun 30, 2026 | 386.63 Mn |
| Mar 31, 2026 | 382.89 Mn |
| Mar 31, 2026 | 382.89 Mn |
| Dec 31, 2025 | -280,000.00 |
| Dec 31, 2025 | -280,000.00 |
| Sep 30, 2025 | 190.73 Mn |
| Sep 30, 2025 | 190.73 Mn |
| Jun 30, 2025 | 106.75 Mn |
| Jun 30, 2025 | 106.75 Mn |
| Mar 31, 2025 | 87.31 Mn |
| Mar 31, 2025 | 87.31 Mn |
| Dec 31, 2024 | 60,000.00 |
| Dec 31, 2024 | 60,000.00 |
| Sep 30, 2024 | 157.18 Mn |
| Sep 30, 2024 | 157.18 Mn |
| Jun 30, 2024 | 153.03 Mn |
| Jun 30, 2024 | 153.03 Mn |
| Mar 31, 2024 | 231.19 Mn |
| Mar 31, 2024 | 231.19 Mn |